Activation of PPARγ redirects fibro-adipogenic progenitors to replace ectopic bone with fat in models of fibrodysplasia ossificans progressiva and trauma-induced heterotopic ossification

This study demonstrates that the FDA-approved PPARγ agonist rosiglitazone effectively redirects fibro-adipogenic progenitors from forming ectopic bone to generating ectopic fat, thereby eliminating heterotopic ossification lesions in mouse models of both fibrodysplasia ossificans progressiva and trauma-induced heterotopic ossification.

The Gist

Imagine your body is a highly skilled construction crew. Usually, this crew knows exactly where to build: bones go in the skeleton, fat goes in the storage depots (like your belly or thighs), and muscle goes where you need to move.

But in two rare and painful conditions—Fibrodysplasia Ossificans Progressiva (FOP) and Trauma-Induced Heterotopic Ossification (HO)—this construction crew gets confused. Instead of building muscle or storing fat, they start building hard, rigid bone in the wrong places, like inside your muscles, tendons, or skin. This is like a construction crew accidentally pouring concrete into your living room sofa. It locks your joints, causes immense pain, and stops you from moving.

The "foreman" of this confused crew is a cell called a Fibro-Adipogenic Progenitor (FAP). Think of FAPs as versatile apprentices who can be trained to become bone, muscle, or fat. In these diseases, the foreman (driven by a faulty signal) screams, "BUILD BONE!" and the apprentices obey, creating hard, immovable masses.

The Big Discovery: Changing the Foreman's Orders

The researchers in this paper asked a simple question: Can we trick the foreman into giving a different order? Instead of screaming "Build Bone!", can we whisper, "Build Fat instead"?

They knew that Fat is soft and flexible, while Bone is hard and rigid. If they could get the construction crew to build fat instead of bone in those wrong places, the patient could move again, and the pain would vanish.

To find the right "whisper," they didn't invent a new drug from scratch. Instead, they used a computer to scan through a library of existing, FDA-approved drugs (drugs already known to be safe for humans) to see which one could flip the switch from "Bone" to "Fat."

The Winning Candidate: Rosiglitazone

The computer pointed to a drug called Rosiglitazone.

• What is it? It's an old drug originally used to treat Type 2 diabetes.
• How does it work? Think of Rosiglitazone as a master key that unlocks the "Fat Factory" inside the cells. It turns on the switch that tells the construction crew, "Okay, stop building concrete; let's make soft, squishy fat instead."

The Experiment: Turning Bone into Fat

The scientists tested this on mice with the same "confused construction crew" problems as humans.

1. The Setup: They injured the mice's muscles to trigger the unwanted bone growth.
2. The Treatment: They gave the mice Rosiglitazone.
3. The Result:
   • Without the drug: The mice grew hard, jagged lumps of extra bone. They couldn't move their legs well.
   • With the drug: The hard bone disappeared. In its place, the mice grew soft, harmless fat.

It was as if the construction crew, instead of pouring concrete into the living room, decided to fill the space with fluffy pillows. The room was still filled, but now it was soft and safe to walk on.

They tested this in two ways:

• Systemic (Whole Body): Giving the drug through the bloodstream.
• Local (Spot Treatment): Injecting the drug right next to the injury.
  Both methods worked perfectly, turning the "bone monsters" into "fat pillows."

Why This Matters

Currently, there are very few treatments for these conditions, and the one approved drug has serious side effects (like stunting growth in children).

This study is exciting because:

1. It's a "Repurposed" Drug: Rosiglitazone is already FDA-approved and known to be safe for humans. This means we don't have to wait 10 years for a new drug to be tested from scratch. We could potentially start testing it on humans much sooner.
2. It Solves the Problem: It doesn't just stop the bone from growing; it actively replaces the bad bone with good, soft fat.
3. It Works for Everyone: It worked on the genetic version (FOP) and the injury version (HO), suggesting it could help a wide range of patients.

The Bottom Line

Imagine your body's construction crew got the wrong blueprint and started building a fortress where a park should be. This paper shows that by using an old, safe key (Rosiglitazone), we can hand the crew a new blueprint that says, "Build a park instead." The result? The fortress melts away, replaced by soft, flexible tissue, allowing people to move and live without pain.

Technical Summary

Title

Activation of PPARγ redirects fibro-adipogenic progenitors to replace ectopic bone with fat in models of fibrodysplasia ossificans progressiva and trauma-induced heterotopic ossification.

1. Problem Statement

Heterotopic Ossification (HO) is a pathological condition where bone forms abnormally within soft tissues. It manifests in two primary forms:

• Fibrodysplasia Ossificans Progressiva (FOP): A genetic disorder caused by a hyperactivating mutation in the BMP receptor ACVR1 (R206H), making it susceptible to activation by inflammatory ligands (e.g., Activin A).
• Trauma-Induced HO: Occurs in patients with wild-type ACVR1 following severe injuries (burns, blast injuries, surgery) due to elevated levels of BMP ligands (e.g., BMP2).

In both conditions, Fibro-Adipogenic Progenitors (FAPs) are the precursor cells that undergo aberrant osteogenic differentiation, leading to rigid ectopic bone. This causes severe morbidity, including loss of mobility, nerve impingement, and open wounds. Current therapeutic options are limited; the only FDA-approved drug, palovarotene, carries significant risks (e.g., premature joint fusion in children). The study hypothesizes that FAPs can be "nudged" away from osteogenesis toward adipogenesis (fat formation), which is mechanically softer and less debilitating than bone.

2. Methodology

The study employed a multi-modal approach combining in silico drug discovery, in vitro cell culture, and in vivo mouse models.

• In Silico Drug Discovery:

  • Analyzed bulk RNA-seq datasets from three mouse models: FOP (GSE220725), trauma-induced HO with dexamethasone (GSE218699), and burn/tenotomy-induced HO (GSE126118).
  • Used the Drug-Gene Interaction Database (DGIdb) to score FDA-approved drugs based on their ability to reverse the dysregulated gene expression signatures observed in HO/FOP lesions.
  • Filtered for non-immunotherapeutic and non-antineoplastic agents.

• In Vitro Experiments:

  • Isolated bone marrow-derived mesenchymal cells from FOP mice (mutant ACVR1) and Wild-Type (WT) mice.
  • Treated cells with osteogenic inducers (Activin A for FOP cells; BMP2 for WT cells) combined with Rosiglitazone (a PPARγ agonist) or vehicle control.
  • Assessed gene expression (RT-qPCR) for osteogenic markers (Col2a1, Aggrecan, Sox9) and adipogenic markers (Lpl, Fabp4).

• In Vivo Mouse Models:

  • FOP Model: Ub.CreERT/ACVR1R206H mice induced with tamoxifen, followed by cardiotoxin-induced muscle injury. Treated with systemic Rosiglitazone (10 mg/kg, twice weekly).
  • Trauma-Induced HO Model: WT C57BL/6 mice subjected to Achilles tendon tenotomy.
    • Systemic Treatment: Rosiglitazone (10 mg/kg, twice weekly).
    • Local Treatment: Direct injection of Rosiglitazone (10 mg/kg) around the injury site (once weekly).
  • Controls: Vehicle (corn oil) or PBS injections.
  • Endpoints: Evaluated at 3 weeks post-injury using Micro-CT, X-ray, histology (H&E, Picrosirius Red, Safranin O/Fast Green), and immunofluorescence (Perilipin-1, PPARγ, pSMAD1/5, PDGFRα).

3. Key Contributions

• Identification of Rosiglitazone: An unbiased computational screen identified Rosiglitazone as the top-scoring FDA-approved therapeutic capable of reversing the transcriptional signatures of both FOP and trauma-induced HO.
• Mechanistic Insight: Demonstrated that FAPs in HO lesions lack adipogenic signaling despite high BMP activity. The study proves that exogenous activation of PPARγ can override the osteogenic drive of BMP signaling.
• Dual Delivery Strategy: Validated that Rosiglitazone is effective via both systemic and local administration, offering flexibility for different clinical scenarios (e.g., systemic for burn patients with widespread risk; local for orthopedic surgery to avoid systemic side effects like osteopenia).
• Cell Fate Reprogramming: Provided direct evidence that the drug does not merely stop bone formation but actively redirects progenitor cells to form ectopic adipose tissue.

4. Key Results

• Computational Validation: Rosiglitazone ranked highest across all three datasets for its predicted ability to counteract the gene expression profiles of HO/FOP.
• In Vitro Fate Switching:
  • In FOP cells (Activin A treated), Rosiglitazone significantly downregulated osteogenic genes (Sox9, Col2a1, Aggrecan) and upregulated adipogenic genes (Lpl, Fabp4).
  • Similar results were observed in WT cells treated with BMP2.
• In Vivo Efficacy (FOP Model):
  • Rosiglitazone treatment resulted in an ~10-fold reduction in ectopic bone volume compared to controls (verified by Micro-CT).
  • Histology confirmed the replacement of bone/cartilage with soft adipose tissue.
  • Immunostaining showed that the new fat cells expressed Perilipin-1, PPARγ, and PDGFRα (a marker for FAPs), confirming their origin.
• In Vivo Efficacy (Trauma Model):
  • Both systemic and local Rosiglitazone treatments significantly reduced ectopic bone and cartilage formation in tenotomy models.
  • Local treatment successfully induced ectopic fat without affecting the contralateral (uninjured) limb, minimizing systemic exposure risks.
• Signaling Context: Despite the presence of elevated BMP signaling (pSMAD1/5) in the treated tissues, the activation of PPARγ successfully suppressed osteogenesis and induced adipogenesis.

5. Significance and Implications

• Therapeutic Repurposing: Rosiglitazone is an existing, FDA-approved drug (historically for Type 2 diabetes) with a known safety profile, potentially allowing for faster clinical translation compared to novel drug development.
• Addressing Unmet Needs: Offers a potential solution for FOP and trauma-induced HO, conditions currently lacking effective treatments. It addresses the limitations of palovarotene, particularly regarding safety in pediatric populations.
• Paradigm Shift: The study challenges the view that BMP signaling inevitably leads to bone; it demonstrates that pharmacological modulation of PPARγ can redirect FAPs to a benign adipogenic fate, converting a rigid, pathological bone lesion into soft, functional fat.
• Clinical Strategy: The success of local delivery suggests a viable strategy for preventing HO in high-risk orthopedic surgeries (e.g., hip arthroplasty) without compromising systemic bone density, while systemic delivery remains an option for severe burn victims.

Conclusion: The authors conclude that Rosiglitazone is a highly promising therapeutic candidate for FOP and trauma-induced HO, capable of eradicating ectopic bone and replacing it with ectopic fat by reprogramming FAPs via PPARγ activation.